N Engl J Med 2022 Nov 03
Prevalence of Mismatch-Repair Deficiency in Rectal Adenocarcinomas.
Related Questions
New answer by Radiation Oncologist at Fox Chase Cancer Center (May 3, 2023)
Neoadjuvant immunotherapy
Specifically, would you consider either neoadjuvant or adjuvant immunotherapy in this setting, or only after recurrence?
New comment by Medical Oncologist at Cancer Center Overlook Hospital ( February 28, 2023)
You pointed out the major limitation of the ATOMIC study being 6 months of FOLFOX. It will be interesting to see this data and how many patients actually received 6 months of ...